Literature DB >> 30176955

Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis.

Jean Addington1, Jacqueline Stowkowy1, Lu Liu1, Kristin S Cadenhead2, Tyrone D Cannon3, Barbara A Cornblatt4, Thomas H McGlashan5, Diana O Perkins6, Larry J Seidman7, Ming T Tsuang2, Elaine F Walker8, Carrie E Bearden9, Daniel H Mathalon10, Olga Santesteban-Echarri1, Scott W Woods5.   

Abstract

BACKGROUND: Much of the interest in youth at clinical high risk (CHR) of psychosis has been in understanding conversion. Recent literature has suggested that less than 25% of those who meet established criteria for being at CHR of psychosis go on to develop a psychotic illness. However, little is known about the outcome of those who do not make the transition to psychosis. The aim of this paper was to examine clinical symptoms and functioning in the second North American Prodrome Longitudinal Study (NAPLS 2) of those individuals whose by the end of 2 years in the study had not developed psychosis.
METHODS: In NAPLS-2 278 CHR participants completed 2-year follow-ups and had not made the transition to psychosis. At 2-years the sample was divided into three groups - those whose symptoms were in remission, those who were still symptomatic and those whose symptoms had become more severe.
RESULTS: There was no difference between those who remitted early in the study compared with those who remitted at one or 2 years. At 2-years, those in remission had fewer symptoms and improved functioning compared with the two symptomatic groups. However, all three groups had poorer social functioning and cognition than healthy controls.
CONCLUSIONS: A detailed examination of the clinical and functional outcomes of those who did not make the transition to psychosis did not contribute to predicting who may make the transition or who may have an earlier remission of attenuated psychotic symptoms.

Entities:  

Keywords:  Attenuated symptoms; clinical high risk; conversion; functioning; psychosis

Mesh:

Year:  2018        PMID: 30176955     DOI: 10.1017/S0033291718002258

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  25 in total

1.  The prodromal phase: Time to broaden the scope beyond transition to psychosis?

Authors:  Fabio Ferrarelli; Daniel Mathalon
Journal:  Schizophr Res       Date:  2020-01-07       Impact factor: 4.939

2.  Delivering on the public health promise of the psychosis risk paradigm.

Authors:  Tyrone D Cannon
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

Review 3.  White Matter Microstructure across the Psychosis Spectrum.

Authors:  Katherine H Karlsgodt
Journal:  Trends Neurosci       Date:  2020-04-26       Impact factor: 13.837

4.  External validation and extension of the NAPLS-2 and SIPS-RC personalized risk calculators in an independent clinical high-risk sample.

Authors:  K Juston Osborne; Vijay A Mittal
Journal:  Psychiatry Res       Date:  2019-06-21       Impact factor: 3.222

5.  Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains.

Authors:  Dana M Allswede; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Daniel H Mathalon; Thomas McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Tyrone D Cannon
Journal:  Am J Psychiatry       Date:  2019-09-06       Impact factor: 18.112

6.  Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis.

Authors:  Jean Addington; Daniel J Devoe; Olga Santesteban-Echarri
Journal:  Curr Treat Options Psychiatry       Date:  2019-01-31

7.  Commentary. Toward a core outcomes assessment set for clinical high risk.

Authors:  Scott W Woods; Catalina V Mourgues-Codern; Albert R Powers
Journal:  Schizophr Res       Date:  2020-05-12       Impact factor: 4.939

Review 8.  Forecasting Remission From the Psychosis Risk Syndrome With Mismatch Negativity and P300: Potentials and Pitfalls.

Authors:  Holly K Hamilton; Brian J Roach; Daniel H Mathalon
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-10-24

9.  Depression: An actionable outcome for those at clinical high-risk.

Authors:  Jean Addington; Megan S Farris; Lu Liu; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; William S Stone; Matcheri Keshevan; Scott W Woods
Journal:  Schizophr Res       Date:  2020-10-29       Impact factor: 4.939

Review 10.  Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis.

Authors:  Meike Heurich; Melanie Föcking; David Mongan; Gerard Cagney; David R Cotter
Journal:  Mol Psychiatry       Date:  2021-07-05       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.